Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
Nikolaus Marx, Melanie J. Davies, Peter J. Grant, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 9, Iss. 1, pp. 46-52
Open Access | Times Cited: 131

Showing 1-25 of 131 citing articles:

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L.J. Visseren, François Mach, Yvo M. Smulders, et al.
European Heart Journal (2021) Vol. 42, Iss. 34, pp. 3227-3337
Open Access | Times Cited: 4328
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L.J. Visseren, François Mach, Yvo M. Smulders, et al.
European Journal of Preventive Cardiology (2021) Vol. 29, Iss. 1, pp. 5-115
Open Access | Times Cited: 382
Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
Liyun He, Jialu Wang, Fan Ping, et al.
JAMA Internal Medicine (2022) Vol. 182, Iss. 5, pp. 513-513
Open Access | Times Cited: 135
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Bo Xu, Shaoqian Li, Bo-Kyeong Kang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 116
All-in-one bioactive properties of photothermal nanofibers for accelerating diabetic wound healing
Yanan Zhao, Chuan Tian, Yiming Liu, et al.
Biomaterials (2023) Vol. 295, pp. 122029-122029
Open Access | Times Cited: 83
Arterial Stiffness: From Basic Primers to Integrative Physiology
Véronique Regnault, Patrick Lacolley, Stéphane Laurent
Annual Review of Physiology (2024) Vol. 86, Iss. 1, pp. 99-121
Open Access | Times Cited: 19
Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension
Alexandros Kasiakogias, Enrico Agabiti Rosei, Miguel Camafort, et al.
Journal of Hypertension (2021) Vol. 39, Iss. 8, pp. 1522-1545
Open Access | Times Cited: 56
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Frank L.J. Visseren, François Mach, Yvo M. Smulders, et al.
Revista Española de Cardiología (2022) Vol. 75, Iss. 5, pp. 429.e1-429.e104
Closed Access | Times Cited: 47
Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer
Nicole Wagner, Kay‐Dietrich Wagner
Cells (2022) Vol. 11, Iss. 15, pp. 2432-2432
Open Access | Times Cited: 45
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
Elena Y. Rykova, Vadim V. Klimontov, Elena Kazakova, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1670-1670
Open Access | Times Cited: 1
Diabetes Mellitus and Heart Failure
Filippos Triposkiadis, Αndrew Xanthopoulos, Αlexandra Bargiota, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 16, pp. 3682-3682
Open Access | Times Cited: 46
Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS
Angel N. Borisov, Alexander Kutz, Emanuel Christ, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 11, pp. 2940-2949
Open Access | Times Cited: 22
Glucagon-like peptide-1 agonists in cardiovascular diseases, a bibliometric analysis from inception to 2023
Abinash Mahapatro, Ali Bozorgi, Sri Usha Jeevani Obulareddy, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 11, pp. 6602-6618
Open Access | Times Cited: 6
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 33
Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 0·9 million adults with Diabetes in Hong Kong (2002–2019)
Aimin Yang, Hongjiang Wu, Eric S. H. Lau, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 26, pp. 100509-100509
Open Access | Times Cited: 25
Peroxisome proliferator‐activated receptors as therapeutic target for cancer
Yuqing Wang, Feifei Lei, Yiyun Lin, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 28, Iss. 5
Open Access | Times Cited: 16
Unveiling Anti-Diabetic Potential of Baicalin and Baicalein from Baikal Skullcap: LC–MS, In Silico, and In Vitro Studies
Wencheng Zhao, Huizi Cui, Kaifeng Liu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3654-3654
Open Access | Times Cited: 5
SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
Xiaodan Wang, Jingyu Ni, Rui Guo, et al.
Heart Failure Reviews (2021) Vol. 27, Iss. 3, pp. 961-980
Closed Access | Times Cited: 31
Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease
Suyan Duan, Lu Fang, Dandan Song, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 29
Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities
Shiying Shao, Xiaoling Zhang, Qinqin Xu, et al.
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108270-108270
Closed Access | Times Cited: 21
To do one and to get more: Part I. Diabetes and bone
Wen-Ling Lee, Peng‐Hui Wang, Szu‐Ting Yang, et al.
Journal of the Chinese Medical Association (2022) Vol. 85, Iss. 10, pp. 965-971
Open Access | Times Cited: 21
Use of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes
Carl-Emil Lim, Björn Pasternak, Björn Eliasson, et al.
European Journal of Preventive Cardiology (2022) Vol. 30, Iss. 8, pp. 634-643
Open Access | Times Cited: 19
Starch-ascorbyl palmitate inclusion complex, a type 5 resistant starch, reduced in vitro digestibility and improved in vivo glycemic response in mice
Jiayue Guo, Amy Ellis, Yanqi Zhang, et al.
Carbohydrate Polymers (2023) Vol. 321, pp. 121289-121289
Closed Access | Times Cited: 13
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon‐like peptide‐1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow‐Up Registry
Heike Jung, Sascha R. Tittel, Nanette C. Schloot, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1813-1822
Open Access | Times Cited: 11
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top